Cargando…
Development of a New Vaccine for the Prevention of Lassa Fever
BACKGROUND: Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and the United States by travelers on commercial airlines from Africa underscores the public health challenge of emerging viruses. Currently, there are no licensed vaccines for Lassa fever, and no experi...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160587/ https://www.ncbi.nlm.nih.gov/pubmed/15971954 http://dx.doi.org/10.1371/journal.pmed.0020183 |
_version_ | 1782124403181486080 |
---|---|
author | Geisbert, Thomas W Jones, Steven Fritz, Elizabeth A Shurtleff, Amy C Geisbert, Joan B Liebscher, Ryan Grolla, Allen Ströher, Ute Fernando, Lisa Daddario, Kathleen M Guttieri, Mary C Mothé, Bianca R Larsen, Tom Hensley, Lisa E Jahrling, Peter B Feldmann, Heinz |
author_facet | Geisbert, Thomas W Jones, Steven Fritz, Elizabeth A Shurtleff, Amy C Geisbert, Joan B Liebscher, Ryan Grolla, Allen Ströher, Ute Fernando, Lisa Daddario, Kathleen M Guttieri, Mary C Mothé, Bianca R Larsen, Tom Hensley, Lisa E Jahrling, Peter B Feldmann, Heinz |
author_sort | Geisbert, Thomas W |
collection | PubMed |
description | BACKGROUND: Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and the United States by travelers on commercial airlines from Africa underscores the public health challenge of emerging viruses. Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge. METHODS AND FINDINGS: We developed a replication-competent vaccine against Lassa virus based on attenuated recombinant vesicular stomatitis virus vectors expressing the Lassa viral glycoprotein. A single intramuscular vaccination of the Lassa vaccine elicited a protective immune response in nonhuman primates against a lethal Lassa virus challenge. Vaccine shedding was not detected in the monkeys, and none of the animals developed fever or other symptoms of illness associated with vaccination. The Lassa vaccine induced strong humoral and cellular immune responses in the four vaccinated and challenged monkeys. Despite a transient Lassa viremia in vaccinated animals 7 d after challenge, the vaccinated animals showed no evidence of clinical disease. In contrast, the two control animals developed severe symptoms including rashes, facial edema, and elevated liver enzymes, and ultimately succumbed to the Lassa infection. CONCLUSION: Our data suggest that the Lassa vaccine candidate based on recombinant vesicular stomatitis virus is safe and highly efficacious in a relevant animal model that faithfully reproduces human disease. |
format | Text |
id | pubmed-1160587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-11605872005-06-29 Development of a New Vaccine for the Prevention of Lassa Fever Geisbert, Thomas W Jones, Steven Fritz, Elizabeth A Shurtleff, Amy C Geisbert, Joan B Liebscher, Ryan Grolla, Allen Ströher, Ute Fernando, Lisa Daddario, Kathleen M Guttieri, Mary C Mothé, Bianca R Larsen, Tom Hensley, Lisa E Jahrling, Peter B Feldmann, Heinz PLoS Med Research Article BACKGROUND: Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and the United States by travelers on commercial airlines from Africa underscores the public health challenge of emerging viruses. Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge. METHODS AND FINDINGS: We developed a replication-competent vaccine against Lassa virus based on attenuated recombinant vesicular stomatitis virus vectors expressing the Lassa viral glycoprotein. A single intramuscular vaccination of the Lassa vaccine elicited a protective immune response in nonhuman primates against a lethal Lassa virus challenge. Vaccine shedding was not detected in the monkeys, and none of the animals developed fever or other symptoms of illness associated with vaccination. The Lassa vaccine induced strong humoral and cellular immune responses in the four vaccinated and challenged monkeys. Despite a transient Lassa viremia in vaccinated animals 7 d after challenge, the vaccinated animals showed no evidence of clinical disease. In contrast, the two control animals developed severe symptoms including rashes, facial edema, and elevated liver enzymes, and ultimately succumbed to the Lassa infection. CONCLUSION: Our data suggest that the Lassa vaccine candidate based on recombinant vesicular stomatitis virus is safe and highly efficacious in a relevant animal model that faithfully reproduces human disease. Public Library of Science 2005-06 2005-06-28 /pmc/articles/PMC1160587/ /pubmed/15971954 http://dx.doi.org/10.1371/journal.pmed.0020183 Text en Copyright: © 2005 Geisbert et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Geisbert, Thomas W Jones, Steven Fritz, Elizabeth A Shurtleff, Amy C Geisbert, Joan B Liebscher, Ryan Grolla, Allen Ströher, Ute Fernando, Lisa Daddario, Kathleen M Guttieri, Mary C Mothé, Bianca R Larsen, Tom Hensley, Lisa E Jahrling, Peter B Feldmann, Heinz Development of a New Vaccine for the Prevention of Lassa Fever |
title | Development of a New Vaccine for the Prevention of Lassa Fever |
title_full | Development of a New Vaccine for the Prevention of Lassa Fever |
title_fullStr | Development of a New Vaccine for the Prevention of Lassa Fever |
title_full_unstemmed | Development of a New Vaccine for the Prevention of Lassa Fever |
title_short | Development of a New Vaccine for the Prevention of Lassa Fever |
title_sort | development of a new vaccine for the prevention of lassa fever |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160587/ https://www.ncbi.nlm.nih.gov/pubmed/15971954 http://dx.doi.org/10.1371/journal.pmed.0020183 |
work_keys_str_mv | AT geisbertthomasw developmentofanewvaccineforthepreventionoflassafever AT jonessteven developmentofanewvaccineforthepreventionoflassafever AT fritzelizabetha developmentofanewvaccineforthepreventionoflassafever AT shurtleffamyc developmentofanewvaccineforthepreventionoflassafever AT geisbertjoanb developmentofanewvaccineforthepreventionoflassafever AT liebscherryan developmentofanewvaccineforthepreventionoflassafever AT grollaallen developmentofanewvaccineforthepreventionoflassafever AT stroherute developmentofanewvaccineforthepreventionoflassafever AT fernandolisa developmentofanewvaccineforthepreventionoflassafever AT daddariokathleenm developmentofanewvaccineforthepreventionoflassafever AT guttierimaryc developmentofanewvaccineforthepreventionoflassafever AT mothebiancar developmentofanewvaccineforthepreventionoflassafever AT larsentom developmentofanewvaccineforthepreventionoflassafever AT hensleylisae developmentofanewvaccineforthepreventionoflassafever AT jahrlingpeterb developmentofanewvaccineforthepreventionoflassafever AT feldmannheinz developmentofanewvaccineforthepreventionoflassafever |